drugset / Trial / NCT01077466
Natalizumab Treatment of Progressive Multiple Sclerosis
Phase 2
Completed
24 enrolled
Rigshospitalet, Denmark
Biogen · collabCopenhagen University Hospital, Hvidovre · collabSignifikans ApS · collabUniversity of Copenhagen · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis. This will be done by measuring the effect of treatment on inflammation in the CNS by means of osteopontin levels in the cerebrospinal fluid (CSF). Safety measures further includes physical and neurological examination,blood samples and MRI measures of disease activity.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | 300 mg | Intravenous |